Pinnacle Associates’s Caribou Biosciences CRBU Stock Holding History

Pinnacle Associates’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.5K	Hold	12,903	–	–	﹤0.01%	954
2025 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	931
2025 Q3	$30.1K	Hold	12,903	–	–	﹤0.01%	862
2025 Q2	$16.3K	Hold	12,903	–	–	﹤0.01%	845
2025 Q1	$11.8K	Hold	12,903	–	–	﹤0.01%	823
2024 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	832
2024 Q3	$73.9K	Hold	12,903	–	–	﹤0.01%	786
2024 Q2	$21.2K	Hold	12,903	–	–	﹤0.01%	810
2024 Q1	$66.3K	Hold	12,903	–	–	﹤0.01%	821
2023 Q4	$73.9K	Hold	12,903	–	–	﹤0.01%	800
2023 Q3	$61.7K	Hold	12,903	–	–	﹤0.01%	795
2023 Q2	$54.8K	Hold	12,903	–	–	﹤0.01%	804
2023 Q1	$68.5K	Hold	12,903	–	–	﹤0.01%	756
2022 Q4	$81K	Hold	12,903	–	–	﹤0.01%	740
2022 Q3	$136K	Hold	12,903	–	–	﹤0.01%	711
2022 Q2	$70K	Buy	+12,903	New	+$98.6K	﹤0.01%	731

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pinnacle Associates's CRBU Position: Q1 2026 in Review

Pinnacle Associates held its Caribou Biosciences (CRBU) position steady in Q1 2026 at 12,903 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Pinnacle Associates first reported a position in CRBU in Q2 2022 and has held it in 16 quarters since. The position peaked at $136K in Q3 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Pinnacle Associates held 12,903 shares of Caribou Biosciences worth $24.5K as of Q1 2026.
Pinnacle Associates left its Caribou Biosciences share count unchanged in Q1 2026.
Caribou Biosciences made up ﹤0.01% of Pinnacle Associates's portfolio in Q1 2026, its #954 holding.
Pinnacle Associates first reported a position in Caribou Biosciences in Q2 2022 and has held it in 16 quarters since.
Pinnacle Associates's Caribou Biosciences position peaked at $136K in Q3 2022.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.